UNITED STATES DISTRICT COURT NORTHERN DISTRICT OF OHIO EASTERN DIVISION

IN RE: NATIONAL PRESCRIPTION OPIATE LITIGATION	MDL No. 2804 Case No. 17-md-2804
This document relates to:	Judge Dan Aaron Polster
The County of Summit, Ohio, et al., v. Purdue Pharma L.P., et al., Case No. 18-OP- 45090 (N.D. Ohio)	
The County of Cuyahoga v. Purdue Pharma L.P., et al., Case No. 17-OP-45004 (N.D. Ohio); and	
<i>City of Cleveland v. AmerisourceBergen Drug Corp., et al., Case No. 18-OP-45132 (N.D. Ohio).</i>	

RESPONSES AND OBJECTIONS OF DEFENDANTS CEPHALON, INC., TEVA PHARMACEUTICALS USA, INC., TEVA PHARMACEUTICAL INDUSTRIES LTD., ACTAVIS LLC, ACTAVIS PHARMA, INC., AND WATSON LABORATORIES, INC. TO PLAINTIFFS' THIRD SET OF INTERROGATORIES

Pursuant to Rule 33 of the Federal Rules of Civil Procedure and the Court's Case

Management Order One (Dkt. No. 232), Defendants Cephalon, Inc. and Teva Pharmaceuticals

USA, Inc. ("Teva"), Defendants Actavis LLC, Actavis Pharma, Inc. f/k/a Watson Pharma, Inc.,

and Watson Laboratories, Inc. ("the Teva-Acquired Actavis Entities") (Teva and the Teva-

Acquired Actavis Entities are referred to collectively as the "Domestic Teva Defendants"), and

Teva Pharmaceutical Industries Ltd. ("Teva Ltd.") (the Domestic Teva Defendants and Teva Ltd.

are referred to collectively as the "Teva Defendants")¹ by and through their undersigned counsel,

¹ The Interrogatories served by Plaintiffs on the Teva-Acquired Actavis Entities improperly grouped them with entities not affiliated with the Teva Defendants. These Responses are made on behalf of the Teva Defendants.



hereby provide the following Responses and Objections ("Responses") to Plaintiffs' Third Set of Interrogatories ("Interrogatories") and state as follows:

PRELIMINARY STATEMENT

1. The Responses are made solely for the purposes of the three cases designated in "Track One" of Case Management Order One ("CMO 1") and are not to be used in connection with any other action except as expressly provided in the Protective Order entered on May 15, 2018, as Case Management Order No. 2 (Dkt. 441).

2. The Responses are based on diligent investigation conducted by the Teva Defendants and their counsel to date, documents and information available to the Teva Defendants at this time, and reflect the Teva Defendants' knowledge, information, and belief as of the date of the Responses. The Responses are true and correct to the Teva Defendants' best knowledge as of this date.

3. The Teva Defendants may engage in further investigation, discovery, and analysis, which may lead to changes in the Teva Defendants' Responses herein. Such investigation and discovery are continuing, and the Responses are given without prejudice to the Teva Defendants' right to produce evidence of any subsequently-discovered facts, documents, or interpretations thereof, or to supplement, modify, change, or amend the Responses, and to correct for errors, mistakes, or omissions. Reference in the Responses to a preceding or subsequent response incorporates both the information and the objections set forth in the referred-to response.

4. The Teva Defendants will make reasonable efforts to respond to every Interrogatory, to the extent the Interrogatory has not been objected to, as the Teva Defendants understand and interpret the Interrogatory. In the event that Plaintiffs subsequently assert an interpretation of an Interrogatory that differs from that of the Teva Defendants, the Teva

Defendants reserve the right to amend and/or supplement their Response, but undertake no obligation to do so.

5. In responding to the Interrogatories, the Teva Defendants do not waive, and hereby expressly reserve: (a) their right to assert any objections as to the competency, relevancy, materiality, privilege, or admissibility as evidence, for any purpose, of any information produced in response to the Interrogatories; (b) their right to object on any ground to the use of the information produced in response to the Interrogatories at any hearing, trial, or other point during the litigation; and (c) their right to object on any ground at any time to a demand for further responses to the Interrogatories.

6. No incidental or implied admissions are intended in these Responses. That the Teva Defendants have responded to all or any part of an Interrogatory should not be taken as, and indeed does not constitute, an admission that the Teva Defendants accept or admit the existence of any fact set forth or assumed by the Interrogatory or that the Teva Defendants' Responses constitute admissible or relevant evidence. That the Teva Defendants have responded to all or any part of an Interrogatory also is not intended to be, and indeed does not constitute, a waiver by the Teva Defendants of all or any part of its objection(s) to the Interrogatory.

7. The following Objections to Definitions and Instructions apply to each and every one of the Interrogatories, and should be considered part of the Teva Defendants' response to each and every one of the Interrogatories. Any specific objections provided below are made in addition to the Objections to Definitions and Instructions, and failure to reiterate an Objection to Definitions and Instructions below does not constitute a waiver or limitation of that or any other objection.

OBJECTIONS TO DEFINITIONS AND INSTRUCTIONS

The Teva Defendants hereby assert the following Objections to Definitions and Instructions, which are hereby incorporated into each of the specific responses and objections to the Interrogatories set forth below.

1. The Teva Defendants object to Plaintiffs' definition of "You" and "Your" as vague and/or ambiguous, overly broad, unduly burdensome, and not proportional to the needs of the case, and thus outside the scope of permissible discovery because it purports to encompass, without limitation, "officers, directors, employees, partners, representatives, agents, corporate parent, subsidiaries, affiliates, divisions, predecessors, or successors-in-interest, and other persons or entities acting on [their] behalf or controlled by" the Teva Defendants. The Teva Defendants will only produce documents in the possession, custody, or control of Cephalon, Inc., Teva Pharmaceuticals USA, Inc., Actavis LLC, Actavis Pharma, Inc. f/k/a Watson Pharma, Inc., or Watson Laboratories, Inc.

2. The Teva Defendants interpret the terms "You" and "Your" as used in these Interrogatories to refer only to Defendants Teva Pharmaceuticals USA, Inc., Cephalon, Inc., Actavis LLC, Actavis Pharma, Inc. f/k/a Watson Pharma, Inc., Watson Laboratories, Inc., and Teva Pharmaceutical Industries Ltd. Defendants expressly exclude other respective subsidiaries or affiliates from the terms "You" and "Your" and no response herein should be interpreted to include such other entities.

3. The Teva Defendants object to Plaintiffs' definition of "You" and "Your" as overly broad, unduly burdensome, and not proportional to the needs of the case, and thus outside the scope of permissible discovery, because it purports to encompass, without limitation, Teva Pharmaceutical Industries Ltd. Teva Pharmaceutical Industries Ltd. is not subject to personal jurisdiction in this action. Teva Pharmaceutical Industries Ltd. is a public limited company incorporated under the laws of Israel and headquartered in Petah Tikva, Israel. It has no office, property, employees, or registered agent in the United States and does not transact business in the United States. At no time has Teva Pharmaceutical Industries Ltd. manufactured, promoted, or sold opioid prescription medicines in the United States. For the Track One discovery cases, none of the Complaints contain any specific allegations concerning promotion by Teva Pharmaceutical Industries Ltd., nor do they allege any wrongful conduct by Teva Pharmaceutical Industries Ltd. that could serve as a basis for any claim against it. Therefore, any non-privileged information that is responsive to these Interrogatories related to Teva Pharmaceutical Industries Ltd., if any exists, is not relevant to this litigation, and would be unduly burdensome to collect and would not be proportionate to any legitimate need by Plaintiffs.

4. The Teva Defendants object to Plaintiffs' definition of "You" and "Your" as overly broad, unduly burdensome, and not proportional to the needs of the case, and thus outside the scope of permissible discovery, because it purports to encompass, without limitation, "Watson Laboratories, Inc., Actavis LLC, and Actavis Pharma, Inc. f/k/a Watson Pharma, Inc." The Teva-Acquired Actavis Entities, which did not become affiliated with any Teva entity until 2016, only sell generic opioid drugs and do not sell, market, or otherwise distribute any branded opioid product. For the Track One discovery cases, none of the Complaints contain any specific allegations concerning promotion by the Teva-Acquired Actavis Entities concerning their generic opioids, nor do they allege any wrongful conduct by those Entities that could serve as a basis for any claim against them. Therefore, any non-privileged information that is responsive to these Interrogatories, if any exists, is not relevant to this litigation, and would be unduly burdensome to collect and would not be proportionate to any legitimate need by Plaintiffs. Nevertheless, the Teva Defendants will provide substantive responses in response to these Interrogatories as set forth in the individual Responses below.

5. The Teva Defendants object to Plaintiffs' definition of "Opioid" to the extent that it means opioids "used to control pain, including, but not limited to, the drugs referenced in Plaintiffs' Complaint in the above-referenced matter" as vague, ambiguous, and overbroad. The Teva Defendants will provide information relating to their Schedule II opioid products, including ACTIQ® (fentanyl citrate) oral transmucosal lozenge CII and FENTORA® (fentanyl buccal tablet) CII. ACTIQ® and FENTORA® are each FDA-approved opioid agonists indicated for the management of breakthrough pain in adult cancer patients who are already receiving and who are tolerant to around-the-clock opioid therapy for their underlying persistent cancer pain. Patients considered opioid tolerant are those who are taking, for one week or longer, around-the-clock medicine consisting of at least 60 mg of oral morphine per day, at least 25 mcg of transdermal fentanyl per hour, at least 30 mg of oral oxycodone per day, at least 8 mg of oral hydromorphone per day, at least 25 mg of oral oxymorphone per day, at least 60 mg of oral hydrocodone per day, or an equianalgesic dose of another opioid daily for a week or longer. Patients must remain on around-the-clock opioids while taking ACTIQ® or FENTORA®.

6. Any information provided by the Teva Defendants in response to requests for information about "Opioids" does not mean that these products were promoted for or "used to control pain" or any other use beyond that which has expressly been approved by the FDA, nor does it suggest that the Teva Defendants ever promoted, marketed, or sold any opioids in the jurisdictions at issue. The Teva Defendants also object to any implication or presupposition that they can or do control or know how any opioid product is "used" once prescribed.

7. The Teva Defendants object to the definition of "Opioid Products" to the extent it incorporates the defined term "Opioid," for the reasons stated above with respect to that defined term.

8. The Teva Defendants object to the definition of "Communication" as calling for the search and collection of sources like "MySpace," "Twitter," and "shared applications from cell phones" that would be unduly burdensome, overbroad, and not proportional to the needs of the case.

9. The Teva Defendants object to the definition of "Document" as overly broad and unduly burdensome to the extent it purports to impose upon the Teva Defendants any obligation inconsistent with the Federal Rules of Civil Procedure.

10. The Teva Defendants object to the use of the phrase "above-captioned matter" to the extent it purports to reference cases other than the three cases included in Track One of the Court's CMO 1.

11. The Teva Defendants object to the definition of "Defendants" to the extent it purports to name Defendants who are not named in the three cases included in Track One of the Court's CMO 1.

12. The Teva Defendants object to the definition of "Plaintiffs" to the extent it purports to name Plaintiffs who are not named in the three cases included in Track One of the Court's CMO1.

13. The Teva Defendants object to the definition of "Person" to the extent it purports to impose obligations to produce information outside of the Teva Defendants' knowledge, possession, custody, and control.

14. The Teva Defendants object to the definition of "Identify" when used with respect to persons, on the ground that it seeks irrelevant information, is overly broad and unduly burdensome, and purports to require the Teva Defendants to produce information outside the possession, custody, or control of the Teva Defendants. In particular, the Teva Defendants object to the definition of "Identify" to the extent it purports to require the Teva Defendants to provide any person's present or last known address and present or last known place of employment.

15. The Teva Defendants object to the definition of "Identify" when used with respect to communications, on the ground that it seeks irrelevant information, is overly broad and unduly burdensome, and purports to require the Teva Defendants to produce information outside the possession, custody, or control of the Teva Defendants.

16. The Teva Defendants object to the definition of "Identify" when used with respect to an Order, on the ground that it seeks irrelevant information, is overly broad and unduly burdensome, and purports to require the Teva Defendants to produce information outside the possession, custody, or control of the Teva Defendants.

17. The Teva Defendants object to the definition of "Suspicious Orders" to the extent it purports to impose upon the Teva Defendants any obligation beyond the scope of the Controlled Substances Act, 21 U.S.C. § 811 et al. ("CSA") and/or 21 CFR 1301.74(b). The Teva Defendants further object to the definition to the extent that it requires the Teva Defendants to have knowledge of Mallinckrodt's internal suspicious order monitoring program.

18. The Teva Defendants object to the definition of "Direct Customer" to the extent it means "other customer" as vague, ambiguous, and overly broad.

19. The Teva Defendants object to the definition of "Downstream Customer" to the extent it means "customer of the Direct Customer that purchased opioids from the Direct

Customer" as vague, ambiguous, and overly broad. The Teva Defendants further object on the ground that this definition purports to require the Teva Defendants to produce information outside the knowledge, possession, custody, or control of the Teva Defendants.

20. The Teva Defendants object to the "Instructions" of the Interrogatories as covering the time period "one year prior to the launch of each relevant Opioid Product through the date of your response" as overly broad and unduly burdensome because it requires them to produce documents that are outside the relevant statute(s) of limitations, are not relevant to the claims in the Complaints, and are not proportional to the needs of the case. Nevertheless, the Teva Defendants will provide information in response to these Interrogatories as set forth in the individual Responses below and in accordance with the Court's Discovery Ruling No. 2 (Dkt. No. 693).

21. The Teva Defendants further object to the "Instructions" of the Interrogatories as not proportional to the needs of the case to the extent that the Interrogatories seek information from the Teva Defendants that was previously obtained, is in the possession of the Plaintiffs, and/or has been deemed produced pursuant to CMO 1.

INTERROGATORIES

INTERROGATORY NO. 32:

Identify each order identified by you (by algorithm or otherwise) as an Order that was of interest, peculiar, actually or potentially a Suspicious Order, or otherwise warranting additional review or investigation to determine whether the Order was a Suspicious Order ("Identified Orders"), and for each such Identified Order: (1) state the reason the order was so identified (e.g., Order of excessive size, unusual frequency, etc.), (2) state whether you reported the order to the DEA; (3) describe any investigation review or due diligence performed by or on behalf of You concerning the Identified Order after it was identified, including whether the Identified Order was a Suspicious Order or whether the Direct or Downstream Customer or other customer that placed the Order was engaged in or facilitating diversion, abuse, or misuse of any Opioid Product; (4) state whether the Identified Order was filled as placed, modified and filled, rejected, or cancelled and the reason(s) contemporaneously cited or provided for any such action; and (5) identify by bates-stamp all documents and communications regarding the order.

RESPONSE TO INTERROGATORY NO. 32:

The Teva Defendants incorporate their Preliminary Statement and Objections to Definitions and Instructions. The Teva Defendants object to Interrogatory No. 32 on the ground that it is overly broad, unduly burdensome, vague, and ambiguous in that it requires the Teva Defendants to identify "each Order" no matter how tangential the relation to the claims and/or defenses. The Teva Defendants further object to Interrogatory No. 23 on the ground that it is overly broad, unduly burdensome, vague and ambiguous in that requires the Teva Defendants to identify orders that were "of interest, peculiar, actually or potentially a Suspicious Order, or otherwise warranting additional review or investigation to determine whether the Order was a Suspicious Order" which is an undefined phrase and not included in the definition of "Suspicious Order." The Teva Defendants further object to Interrogatory No. 32 to the extent it purports to encompass orders outside the scope of the CSA, 21 U.S.C. § 811 et al. and/or 21 CFR 1301.74(b). The Teva Defendants further object to Interrogatory No. 32 to the extent it is not reasonably limited in time or scope. The Teva defendants further object to Interrogatory No. 32 to the extent it seeks information about orders for non-Opioid drugs.

Subject to and without waiver of the foregoing objections, and pursuant to Federal Rule of Civil Procedure 33(d), the Domestic Teva Defendants refer Plaintiffs to business records that the Teva Defendants have already produced in this litigation. Those documents contain the information sought by Interrogatory No. 32 and the burden of ascertaining the requested information from those documents is the same for both parties. The Domestic Teva Defendants state that, based on their reasonable investigation to date, they have produced the following documents responsive to Interrogatory No. 32:

- Two SORDS and DefOPS pended order reports: TEVA_MDL_13583538 and TEVA_MDL_13583539;
- All Suspicious Order Reports: Appendix A; and
- Investigation documents related to Publix, Kroger, McKesson, Rochester Drug Cooperative, and Rickie's Pharmacal: Appendix B.

The Domestic Teva Defendants further respond that they have produced their Suspicious Order Monitoring Shared Folders as well as the custodial files of Joe Tomkiewicz and Colleen McGinn with respect to Teva and Tom Napoli, Rachelle Galant, and Nancy Baran with respect to the Teva-Acquired Actavis entities. These files include any investigation materials related to suspicious orders including: new customer due diligence, existing customer due diligence, correspondence with customers regarding pended orders, and internal documents regarding investigations of pended orders. The produced files can be found as follows:

- Suspicious Order Monitoring Shared Folders: TEVA_MDL_A_00694812— TEVA_MDL_A_04205785;
- Joe Tomkiewicz: Teva Production Volumes 9, 15, 18, 19, 20, 22, 23, 24, 29, 30, 31, 31, 37;
- Colleen McGinn: Teva Production Volumes 1, 8, 9, 15, 18, 19, 20, 22, 23, 24, 29, 30, 31, 32, 35, 38, 39, 42;
- Tom Napoli: Acquired Actavis Production Volumes 2, 3, 5, 7, 11, 16;

- Rachelle Galant: Acquired Actavis Production Volumes 1, 2, 3, 5, 7, 8, 11;
- Nancy Baran: Acquired Actavis Production Volumes 5, 7, 8, 11, 13, 15; and Teva Production Volumes 43, 46.

Teva Ltd. responds that it is a public limited company incorporated under the laws of Israel and headquartered in Petah Tikva, Israel. Teva Ltd. has no office, property, employees, or registered agent in the United States and does not transact business in the United States. At no time has Teva Ltd. manufactured, promoted, or sold opioid prescription medicines in the United States. Teva Ltd. is not subject to personal jurisdiction in this action and has no information responsive to Interrogatory No. 32.

INTERROGATORY NO. 33:

For each Opioid Product (branded or generic) You manufactured, marketed, promoted, sold or distributed in the United States, provide an annual summary, including for each Opioid Product (1) the product name; (2) the NDC Code(s) for that Opioid Product; (3) the NDC Code(s) holder for that Opioid Product; (4) your role with regard to the product (manufacturer, marketer, seller, distributor, etc.); (5) annual sales by script volume for that Opioid Product; (7) annual sales volume by number of SKU units/bottles for that Opioid Product; (8) annual gross dollar sales for that Opioid Product; and (9) the Documents relied upon to generate the summary.

The summary shall include all currently distributed Opioid Products as well as discontinued Opioid Products. As set forth in the definition of "You" and "Your" herein, the summary shall include the Opioid Products manufactured, marketed, promoted, sold or distributed by You or Your corporate parent, subsidiaries, affiliates, divisions, predecessors or successors-in-interest, and other persons or entities acting on Your behalf or controlled by You.

RESPONSE TO INTERROGATORY NO. 33:

The Teva Defendants incorporate their Preliminary Statement and Objections to Definitions and Instructions. The Teva Defendants object to Interrogatory No. 33 on the ground that it is vague, ambiguous, and overly broad because the definition of "Opioid" is opioids that are "used to control pain." ACTIQ® and FENTORA® are each FDA-approved opioid agonists indicated for the management of breakthrough pain in adult cancer patients who are already receiving and who are tolerant to around-the-clock opioid therapy for their underlying persistent cancer pain. The Teva Defendants further object to Interrogatory No. 33 on the ground that it is not reasonably limited in time or scope. The Teva Defendants further object to Interrogatory No. 33 on the ground that Plaintiffs request the Teva Defendants to develop Plaintiff's affirmative case. The Teva Defendants further object to Interrogatory No. 33 on the ground that the information sought is not relevant to the claims in the Complaints and is therefore not proportional to the needs of the Track One cases.

Subject to and without waiver of the foregoing objections, and pursuant to Federal Rule of Civil Procedure 33(d), the Domestic Teva Defendants refer Plaintiffs to business records that the Teva Defendants have already produced in this litigation. Those documents contain the information sought by Interrogatory No. 33 and the burden of ascertaining the requested information from those documents is the same for both parties. The Domestic Teva Defendants state that, based upon their reasonable investigation to date, they have identified documents that contain the following information related to ACTIQ® and FENTORA® responsive to Interrogatory No. 33:

• Profit data for ACTIQ® and FENTORA® from 2006 through the first quarter of 2012;

- Chargeback data for ACTIQ® and FENTORA® from 2011 through April, 2018;
- National monthly sales for ACTIQ[®] and FENTORA[®] from April, 2012 through March, 2018;
- All Accounts Receivable Transactional Data for ACTIQ® and FENTORA® from April, 2012 through April, 2018;
- Budgets and actuals of units sold, and sales and marketing expenses for FENTORA® from 2013 through 2016; and
- Cephalon sales and related reporting data from 2002 through 2006.

The Domestic Teva Defendants further state that, based upon their reasonable investigation to date, they have identified documents that contain the following information related to generic opioid products responsive to Interrogatory No. 33:

- Annual Generics Total Unit Sales, Sales Doses, and Total Net Sales from fiscal year 2011 through fiscal year 2017;
- Net Sales, Units, Cost of Goods, Royalties, and Gross Margin for Teva Pharmaceuticals USA by quarter from 2012 through 2015;
- Net Sales, Units, Cost of Goods, Royalties, and Gross Margin for Teva-Acquired Actavis entities by quarter from 2014 through 2015;
- Net Sales, Units, Cost of Goods, Royalties, and Gross Margin for Teva Pharmaceuticals USA and Teva-Acquired Actavis entities by quarter from 2016 through 2017;
- All Accounts Receivable Transactional Data for Teva Pharmaceuticals USA from 2008 through June, 2018; and
- All Accounts Receivable Transactional Data for Teva-Acquired Actavis entities from the first quarter of 2013 through June, 2018.

The Domestic Teva Defendants further state that, based upon their reasonable investigation to date, they have identified documents that contain the following information related to both ACTIQ® and FENTORA® and generic opioid products responsive to Interrogatory No. 33:

- Sales data by contract from the Domestic Teva Defendants; and
- Indirect and direct sales data from Teva-Acquired Actavis entities and Watson Laboratories Inc.

The Bates numbers of the responsive documents are listed in Appendix C. Further, the requested sales and related reporting data from Cephalon for 2002 through 2006 can be found at TEVA MDL A 06673768 -- TEVA MDL A 06744894.

Teva Ltd. responds that it is a public limited company incorporated under the laws of Israel and headquartered in Petah Tikva, Israel. Teva Ltd. has no office, property, employees, or registered agent in the United States and does not transact business in the United States. At no time has Teva Ltd. manufactured, promoted, or sold opioid prescription medicines in the United States. Teva Ltd. is not subject to personal jurisdiction in this action and has no information responsive to Interrogatory No. 33.

INTERROGATORY NO. 34:

Provide an annual sales summary for Your name-brand and generic Opioid Products You manufactured, marketed, promoted, sold or distributed in the United States including for each year (1) Your total sales volume for those Opioid Products; (2) the total market volume for those Opioid Products; (3) Your market share for those Opioid Products; and (4) Your total annual dollar sales for those Opioid Products; and (5) the Documents relied upon to generate the summary.

The summary shall include all currently distributed Opioid Products as well as discontinued Opioid Products. As set forth in the definition of "You" and "Your" herein, the

summary shall include the Opioid Products manufactured, marketed, promoted, sold or distributed by You or Your corporate parent, subsidiaries, affiliates, divisions, predecessors or successors-ininterest, and other persons or entities acting on Your behalf or controlled by You.

RESPONSE TO INTERROGATORY NO. 34:

The Teva Defendants incorporate their Preliminary Statement and Objections to Definitions and Instructions. The Teva Defendants object to Interrogatory No. 34 on the ground that it is vague, ambiguous, and overly broad because the definition of "Opioid" is opioids that are "used to control pain." ACTIQ® and FENTORA® are each FDA-approved opioid agonists indicated for the management of breakthrough pain in adult cancer patients who are already receiving and who are tolerant to around-the-clock opioid therapy for their underlying persistent cancer pain. The Teva Defendants further object to Interrogatory No. 34 on the ground that it is not reasonably limited in time or scope. The Teva Defendants further object to Interrogatory No. 34 on the ground that Plaintiffs request the Teva Defendants to develop Plaintiff's affirmative case. The Teva Defendants further object to Interrogatory No. 34 on the ground that the information sought is not relevant to the claims in the Complaints and is therefore not proportional to the needs of the Track One cases. The Teva Defendants further object to Interrogatory No. 34 on the ground that parts one and four are duplicative of information requested in Interrogatory No. 33.

Subject to and without waiver of the foregoing objections, the Teva Defendants incorporate their response to Interrogatory No. 33. Subject to and without waiver of the foregoing objections, and pursuant to Federal Rule of Civil Procedure 33(d), the Domestic Teva Defendants further refer Plaintiffs to business records that the Teva Defendants have already produced in this litigation. Those documents contain the information sought by Interrogatory No. 34 and the burden of ascertaining the requested information from those documents is the same for both parties. The Domestic Teva Defendants state that, based upon their reasonable investigation to date, they have identified the following documents that contain information related to the market share and market volume of their opioid products. The produced files can be found as follows:

- Teva's total domestic market share from 2012 through 2016 at TEVA_MDL_A_00455086;
- Documents related to FENTORA® market research beginning in 2013 at TEVA_MDL_A_06494509 -- TEVA_MDL_A_06521881; and
- Documents that contain market share and market volume for all Domestic Teva Defendant products, including products manufactured by acquired entities, from 2000 through 2018: TEVA_MDL_A_07937357 -- TEVA_MDL_A_07954472.

Teva Ltd. responds that it is a public limited company incorporated under the laws of Israel and headquartered in Petah Tikva, Israel. Teva Ltd. has no office, property, employees, or registered agent in the United States and does not transact business in the United States. At no time has Teva Ltd. manufactured, promoted, or sold opioid prescription medicines in the United States. Teva Ltd. is not subject to personal jurisdiction in this action and has no information responsive to Interrogatory No. 34.

Dated: January 7, 2019

Respectfully submitted,

<u>/s/ Steven A. Reed</u> Steven A. Reed Rebecca Hillyer MORGAN, LEWIS & BOCKIUS LLP 1701 Market Street Philadelphia, PA 19103-2921 Phone: (215) 963-5000 Fax: (215) 963-5001 Email: steven.reed@morganlewis.com Email: rebecca.hillyer@morganlewis.com

Wendy West Feinstein MORGAN, LEWIS & BOCKIUS LLP One Oxford Centre, 32nd Fl. Pittsburgh, PA 15219-6401 Phone: (412) 560-7455 Fax: (412) 560-7001 Email: wendy.feinstein@morganlewis.com

Attorneys for Defendants Cephalon, Inc., Teva Pharmaceuticals USA, Inc., Actavis LLC, Actavis Pharma, Inc. f/k/a Watson Pharma, Inc., and Watson Laboratories, Inc.

CERTIFICATE OF SERVICE

I HEREBY CERTIFY that on this 7th day of January 2019, the foregoing has been served via email only to the following liaison counsel:

Liaison Counsel for Plaintiffs:

Peter Henry Weinberger SPANGENBERG SHIBLEY & LIBER LLP 1001 Lakeside Avenue East, Suite 1700 Cleveland, OH 44114-1149 (216) 696-3232 pweinberger@spanglaw.com

Steven J. Skikos SKIKOS CRAWFORD SKIKOS & JOSEPH One Sansome Street, Suite 2830 San Francisco, CA 94104 (415) 546-7300 sskikos@skikoscrawford.com

Troy A. Rafferty LEVIN PAPANTONIO THOMAS MITCHELL RAFFERTY & PROCTOR PA 316 S. Baylen Street, Suite 600 Pensacola, FL 32502 (805) 435-7000 trafferty@levinlaw.com

Liaison Counsel for Defendants:

Mark Cheffo, Esq. Quinn Emanuel 51 Madison Avenue New York, NY 10010 markcheffo@quinnemanuel.com

Carol Rendon, Esq. Baker Hostetler Key Tower, 127 Public Square Cleveland, OH 44114 crendon@bakerlaw.com

Enu Mainigi, Esq. Williams & Connolly 725 Twelfth Street, NW. Washington, DC 20005 emainigi@wc.com Shannon McClure, Esq. ReedSmith Three Logan Square 1717 Arch Street, Suite 3100 Philadelphia, PA 19103 smcclure@reedsmith.com

Geoffrey E. Hobart, Esq. Covington & Burling One CityCenter 850 Tenth Street, NW. Washington, DC 20001 ghobart@cov.com

Kaspar Stoffelmayr, Esq. Bartlit Beck 54 West Hubbard Street, Ste 300 Chicago, IL 60654 Kaspar.stoffelmayr@bartlit-beck.com

Tina Tabacchi, Esq. Jones Day 77 West Wacker Drive Chicago, IL 60601 tmtabacchi@jonesday.com

Tyler Tarney, Esq. Gordon & Rees 41 S. High Street, Suite 2495 Columbus, OH 43215 ttarney@grsm.com

/s/ Wendy West Feinstein

Wendy West Feinstein

APPENDIX A

Bates Numbers
TEVA MDL A 02342525
TEVA_MDL_A_02342526
TEVA MDL A 02063701
TEVA_MDL_A_06532584
TEVA_MDL_A_02342529
TEVA MDL A 01061035
TEVA_MDL_A_02342527
TEVA_MDL_A_01056173
TEVA_MDL_A_01056175
TEVA_MDL_A_01056177
TEVA_MDL_A_01047432
TEVA_MDL_A_02342528
TEVA_MDL_A_02479933
TEVA_MDL_A_02479934
TEVA_MDL_A_02479935
TEVA_MDL_A_02479936
TEVA_MDL_A_02479937
TEVA_MDL_A_02345901
TEVA_MDL_A_02345902
TEVA_MDL_A_02345903
TEVA_MDL_A_02345904
TEVA_MDL_A_02345905
TEVA_MDL_A_02924242
TEVA_MDL_A_02924243
TEVA_MDL_A_01061036
TEVA_MDL_A_01058233
TEVA_MDL_A_01058231
TEVA_MDL_A_01058101
TEVA_MDL_A_01061046
TEVA_MDL_A_01058098
TEVA_MDL_A_01061039
TEVA_MDL_A_01061038
TEVA_MDL_A_02248780
TEVA_MDL_A_02248777
TEVA_MDL_A_01058228
TEVA_MDL_A_01058103
TEVA_MDL_A_01061041
TEVA_MDL_A_02248786
TEVA_MDL_A_02248782
TEVA_MDL_A_02248788
TEVA_MDL_A_04205312
TEVA_MDL_A_04205314

Deter Merry Learn
Bates Numbers
TEVA_MDL_A_04205295
TEVA_MDL_A_04205782
TEVA_MDL_A_04205293
TEVA_MDL_A_04205784
TEVA_MDL_A_02248790
TEVA MDL A 02248792
TEVA MDL A 02248800
TEVA MDL A 02248798
TEVA MDL A 02248796
TEVA_MDL_A_02924759
TEVA_MDL_A_02924761
TEVA_MDL_A_02924763
TEVA_MDL_A_02248803
TEVA_MDL_A_02248805
TEVA_MDL_A_02248804
TEVA_MDL_A_02248089
TEVA_MDL_A_02248090
TEVA_MDL_A_02248091
TEVA_MDL_A_02248092
TEVA_MDL_A_02248093
TEVA_MDL_A_01061043
TEVA_MDL_A_01057274
TEVA_MDL_A_01057277
TEVA_MDL_A_01057584
TEVA_MDL_A_01057586
TEVA_MDL_A_01057589
TEVA_MDL_A_01057590
TEVA_MDL_A_01057593
TEVA_MDL_A_01057596
TEVA_MDL_A_01057598
TEVA_MDL_A_01057601
TEVA MDL A 01057602
TEVA_MDL_A_01057604
TEVA_MDL_A_01057606
TEVA_MDL_A_01057608
TEVA_MDL_A_01057610
TEVA_MDL_A_01057612
TEVA_MDL_A_01057613
TEVA_MDL_A_01049461
TEVA_MDL_A_01049463
TEVA_MDL_A_01057194
TEVA_MDL_A_01061044

APPENDIX B

Bates Ranges
TEVA_MDL_A_00694812 - TEVA_MDL_A_00694904
TEVA_MDL_A_01037238 - TEVA_MDL_A_01061046
TEVA_MDL_A_01457914 - TEVA_MDL_A_01523919
TEVA_MDL_A_02004944 - TEVA_MDL_A_02064191
TEVA_MDL_A_02248089 - TEVA_MDL_A_02249000
TEVA_MDL_A_02332330 - TEVA_MDL_A_02342553
TEVA_MDL_A_02473998 - TEVA_MDL_A_02546025
TEVA_MDL_A_02660740 - TEVA_MDL_A_02665209
TEVA_MDL_A_02915381 - TEVA_MDL_A_02925681
TEVA_MDL_A_03160095 - TEVA_MDL_A_03160098
TEVA_MDL_A_03413868 - TEVA_MDL_A_03486105
TEVA_MDL_A_04204900 - TEVA_MDL_A_04205784
TEVA_MDL_A_04321882 - TEVA_MDL_A_04322496
TEVA_MDL_A_06531642 - TEVA_MDL_A_06533129
TEVA_MDL_A_06618575 - TEVA_MDL_A_06620156
TEVA_MDL_A_06858568 - TEVA_MDL_A_06860516
TEVA_MDL_A_06926270 - TEVA_MDL_A_06927447
TEVA_MDL_A_07150380 - TEVA_MDL_A_07151104
TEVA_MDL_A_08077268 - TEVA_MDL_A_08077306
TEVA_MDL_A_08834972 - TEVA_MDL_A_08835484

APPENDIX C

Bates Numbers
TEVA_MDL_A_00455085
TEVA_MDL_A_02401117
TEVA_MDL_A_02401118
TEVA_MDL_A_02401119
TEVA_MDL_A_02416208
TEVA_MDL_A_02419958
TEVA_MDL_A_02419961
TEVA_MDL_A_02419959
TEVA_MDL_A_02419966
TEVA_MDL_A_02419967
TEVA_MDL_A_02419969
TEVA_MDL_A_02419968
TEVA_MDL_A_02419963
TEVA_MDL_A_02419960
TEVA_MDL_A_02419964
TEVA_MDL_A_02419965
TEVA_MDL_A_02419962
TEVA_MDL_A_02416192
TEVA_MDL_A_02416194
TEVA_MDL_A_02416195
TEVA_MDL_A_02416196
TEVA_MDL_A_02416197
TEVA_MDL_A_02416198
TEVA_MDL_A_02416199
TEVA_MDL_A_02416200
TEVA_MDL_A_02416201
TEVA_MDL_A_02416202

Bates Numbers
TEVA_MDL_A_02416203
TEVA_MDL_A_02416204
TEVA_MDL_A_02416193
TEVA_MDL_A_02416205
TEVA_MDL_A_02416206
TEVA_MDL_A_07869902
TEVA_MDL_A_07876854
TEVA_MDL_A_07880643
TEVA_MDL_A_07885150
TEVA_MDL_A_07889185
TEVA_MDL_A_07889289
TEVA_MDL_A_07901020
TEVA_MDL_A_07907289
TEVA_MDL_A_07914958
TEVA_MDL_A_07921677
TEVA_MDL_A_07921926
TEVA_MDL_A_07921927
TEVA_MDL_A_07921928
TEVA_MDL_A_07928169
TEVA_MDL_A_08637278
TEVA_MDL_A_08637279
TEVA_MDL_A_08637273
TEVA_MDL_A_08637274
TEVA_MDL_A_08637275
TEVA_MDL_A_08637276
TEVA_MDL_A_08637277



December 1, 2014

Drug Enforcement Administration Attn: Donetta Spears Diversion Program Manager William J. Green Federal Building 600 Arch Street, Room 10224 Philadelphia, PA 19106

Re: Suspicious Order Report

Dear Ms. Spears,

In accordance with 21C.F.R. § 1301.74(b), I am submitting this report of controlled substance orders we have deemed to be suspicious. All orders were placed by the following registrant:


Richie Pharmacal LLC 119 State Avenue Glasgow, KY 42141 RR0355683

Date	Product	NDC	Size	Quantity	Total Dosage Units
10/23/2014	ACETAMINOPHEN & CODEINE TB 300/30MG	00093-0150-01	100	40	4,000
10/23/2014	ACETAMINOPHEN & CODEINE TB 300/60MG	00093-0350-01	100	90	9,000
10/23/2014	ACETAMINOPHEN & CODEINE TB 300/60MG	00093-0350-05	500	48	24,000
10/24/2014	ACETAMINOPHEN & CODEINE TB 300/60MG	00093-0350-01	100	50	5,000
10/24/2014	ACETAMINOPHEN & CODEINE TB 300/60MG	00093-0350-05	500	48	24,000

Additionally, pursuant to our investigation, we have suspended all sales of controlled substances to this registrant, pending any further investigation, if it shall become warranted. If you have any questions or concerns, or need any further information, feel free to contact me. My office number is 215.293.6378.

Sincerely,

Joseph Tomkiewicz Diversion Operations Manager Teva Pharmaceuticals



April 18, 2015

Drug Enforcement Administration Attn: Donetta Spears Diversion Program Manager William J. Green Federal Building 600 Arch Street, Room 10224 Philadelphia, PA 19106

Re: Suspicious Order Report

Dear Ms. Spears,

In accordance with 21C.F.R. § 1301.74(b), I am submitting this report of controlled substance orders we have deemed to be suspicious. The orders were placed by the following registrant:


Osborn Drugs 103 S Main Miami, OK 74354 R00470601

Date	Product	NDC	Size	Quantity	Total Dosage Units
4/8/2016	BUPREN/NALOXONE SL TAB 8MG/2MG 30	00093-5721-56	30	48	1,440
1					

Redaction - Other Teva Product

If you have any questions or concerns, or need any further information, feel free to contact me. My office number is 215.293.6378.

Sincerely,



December 13, 2017

Drug Enforcement Administration Attn: Luke Braxton Diversion Program Manager William J. Green Federal Building 600 Arch Street, Room 10224 Philadelphia, PA 19106

Re: Suspicious Order Report

Dear Mr. Braxton,


In accordance with 21C.F.R. § 1301.74(b), I am submitting this report of orders we have deemed to be suspicious. The orders were placed by the following company:

AVA KEROLOS GOOD SAMARITAN PHARMACY 33130 US HIGHWAY 19N PALM HARBOR, FL 34683 FA5044691

From the following company:


DIXON-SHANE LLC D/B/A R & S NORTHEAST LLC 10049 SANDMEYER LANE PHILADELPHIA, PA 19116 RD0289656

Date	Invoice	Product	NDC	Size	Quantity	Total Dosage Units
8/22/2017	140839	OXYCODONE HCL 30MG TAB	00228-2879-11	100	6	600
8/22/2017	140840	OXYCODONE HCL 30MG TAB	00228-2879-11	100	6	600
8/23/2017	140884	OXYCODONE HCL 30MG TAB	00228-2879-11	100	6	600
8/30/2017	141599	OXYCODONE HCL 30MG TAB	00228-2879-11	100	6	600
9/7/2017	142238	OXYCODONE HCL 30MG TAB	00228-2879-11	100	6	600
9/14/2017	142886	OXYCODONE HCL 30MG TAB	00228-2879-11	100	6	600
9/20/2017	143484	OXYCODONE HCL 30MG TAB	00228-2879-11	100	6	600
9/27/2017	144187	OXYCODONE HCL 30MG TAB	00228-2879-11	100	6	600
10/5/2017	144882	OXYCODONE HCL 30MG TAB	00228-2879-11	100	6	600
10/11/2017	145267	OXYCODONE HCL 30MG TAB	00228-2879-11	100	6	600
10/18/2017	145843	OXYCODONE HCL 30MG TAB	00228-2879-11	100	1	100
10/27/2017	146595	OXYCODONE HCL 30MG TAB	00228-2879-11	100	6	600
10/27/2017	146598	OXYCODONE HCL 30MG TAB	00228-2879-11	100	5	500
11/1/2017	147170	OXYCODONE HCL 30MG TAB	00228-2879-11	100	6	600



Accordingly, Teva has suspended DIXON-SHANE, LLC's ability to purchase all oxycodone products pending the results of our investigation. If you have any questions or concerns, or need any further information, feel free to contact me. My office number is 215.293.6378.

Sincerely,



January 16, 2018

Drug Enforcement Administration Attn: Luke Braxton Diversion Program Manager William J. Green Federal Building 600 Arch Street, Room 10224 Philadelphia, PA 19106

Re: Suspicious Order Report

Dear Mr. Braxton,


In accordance with 21C.F.R. § 1301.74(b), I am submitting this report of controlled substance orders we have deemed to be suspicious. The orders were placed by the following registrant:

DIXON-SHANE LLC D/B/A R & S NORTHEAST LLC 10049 SANDMEYER LANE PHILADELPHIA, PA 19116 RD0289656

Date	Product	NDC	Size	Quantity	Total Dosage Units
1/10/2018	OXYCODONE HCL 30MG TABLETS	00228-2879-11	100	48	4,800

If you have any questions or concerns, or need any further information, feel free to contact me. My office number is 215.293.6378.

Sincerely,



April 18, 2018

Drug Enforcement Administration Attn: Luke Braxton Diversion Program Manager William J. Green Federal Building 600 Arch Street, Room 10224 Philadelphia, PA 19106


Re: Suspicious Order Report

Dear Mr. Braxton,

In accordance with 21C.F.R. § 1301.74(b), I am submitting this report of controlled substance orders we have deemed to be suspicious. The orders were placed by the following registrant:


DIXON-SHANE LLC D/B/A R & S NORTHEAST LLC 10049 SANDMEYER LANE PHILADELPHIA, PA 19116 RD0289656

Date	Product	NDC	Size	Quantity	Total Dosage Units
1/17/2018	BUPREN/NALOX 8/2MG SL TABLETS	00228-3155-73	30	24	720
1/17/2018	ACETAMINOPHEN & CODEINE TB 300/30MG	00093-0150-01	100	10	1,000
				Dree	d
Ke	edaction - Ot	ner ie	eva	Pro	auct
2/2/2018		00501 2012 05	500	12	C 000
2/2/2018	HYDROCODONE/APAP 10/325MG TAB	00591-2612-05	500	12	6,000
	Redaction - Of	her Tev	IAP	rodu	ct
				IOGG	
2/9/2018	HYDROCODONE/APAP 10/325MG TAB	00591-2612-05	500	12	6,000
				D	- 1
KE	edaction - Ot	ner le	eva	Pro	duct
	BUPREN/NALOX 8/2MG SL TABLETS	00228-3155-73	30	24	720
3/15/2018			400	10	1.000
3/15/2018 3/21/2018	ACETAMINOPHEN & CODEINE TB 300/30MG	00093-0150-01	100	10	1,000



Additionally, pursuant to our investigation, we have suspended all sales of controlled substances to this registrant. If you have any questions or concerns, or need any further information, feel free to contact me. My office number is 215.293.6378.

Sincerely,



April 18, 2018

Drug Enforcement Administration Attn: Luke Braxton Diversion Program Manager William J. Green Federal Building 600 Arch Street, Room 10224 Philadelphia, PA 19106


Re: Suspicious Order Report

Dear Mr. Braxton,

In accordance with 21C.F.R. § 1301.74(b), I am submitting this report of controlled substance orders we have deemed to be suspicious. The orders were placed by the following registrant:


DIXON-SHANE LLC D/B/A R & S NORTHEAST LLC 10049 SANDMEYER LANE PHILADELPHIA, PA 19116 RD0289656

Date	Product	NDC	Size	Quantity	Total Dosage Units
1/17/2018	BUPREN/NALOX 8/2MG SL TABLETS	00228-3155-73	30	24	720
1/17/2018	ACETAMINOPHEN & CODEINE TB 300/30MG	00093-0150-01	100	10	1,000
				Dree	d
Ke	edaction - Ot	ner ie	eva	Pro	auct
2/2/2018		00501 2012 05	500	12	C 000
2/2/2018	HYDROCODONE/APAP 10/325MG TAB	00591-2612-05	500	12	6,000
	Redaction - Of	her Tev	IAP	rodu	ct
				IOGG	
2/9/2018	HYDROCODONE/APAP 10/325MG TAB	00591-2612-05	500	12	6,000
				D	- 1
KE	edaction - Ot	ner le	eva	Pro	duct
	BUPREN/NALOX 8/2MG SL TABLETS	00228-3155-73	30	24	720
3/15/2018			400	10	1.000
3/15/2018 3/21/2018	ACETAMINOPHEN & CODEINE TB 300/30MG	00093-0150-01	100	10	1,000



Additionally, pursuant to our investigation, we have suspended all sales of controlled substances to this registrant. If you have any questions or concerns, or need any further information, feel free to contact me. My office number is 215.293.6378.

Sincerely,



January 23, 2018

Drug Enforcement Administration Attn: Luke Braxton Diversion Program Manager William J. Green Federal Building 600 Arch Street, Room 10224 Philadelphia, PA 19106

Re: Suspicious Order Report

Dear Mr. Braxton,

In accordance with 21C.F.R. § 1301.74(b), I am submitting this report of controlled substance orders we have deemed to be suspicious. The orders were placed by the following registrant:

ROCHESTER DRUG CO-OPERATIVE INC NJ 116 LEHIGH DRIVE FAIRFIELD, NJ 07004 RR0480676

Date	Product	NDC	Size	Quantity	Total Dosage Units
1/18/2018	ARMODAFINIL TABLETS 150 MG	00093-3092-56	30	6	180
1/18/2018	BUPREN/NALOX 2/0.5MG TABLETS	00228-3154-73	30	24	720
1/18/2018	BUTAL/APAP/CAF/COD 50/325/40/30MG CAP	00591-3220-01	100	1	100
1/18/2018	CARISOPRODOL 350MG TABLETS	00591-5513-01	100	11	1,100
1/18/2018	ESTAZOLAM 2MG TABLETS	00591-0745-01	100	1	100
1/18/2018	LORAZEPAM 0.5MG TABLETS	00591-0240-10	1000	54	54,000
1/18/2018	LORAZEPAM 0.5MG TABLETS	00591-0240-05	500	36	18,000
1/18/2018	LORAZEPAM 1MG TABLETS	00591-0241-01	100	48	4,800
1/18/2018	LORAZEPAM 1MG TABLETS	00591-0241-10	1000	18	18,000
1/18/2018	LORAZEPAM 1MG TABLETS	00591-0241-05	500	12	6,000
1/18/2018	LORAZEPAM 2MG TABLETS	00591-0242-01	100	12	1,200
1/18/2018	MODAFINIL 100MG TABLETS	00591-3499-30	30	18	540
1/18/2018	OXAZEPAM 15MG CAPSULES	00228-2069-10	100	36	3,600
1/18/2018	TEMAZEPAM 15MG CAPSULES	00228-2076-10	100	24	2,400
1/22/2018	ACETAMINOPHEN & CODEINE TB 300/30MG	00093-0150-01	100	30	3,000
1/22/2018	ACETAMINOPHEN & CODEINE TB 300/60MG	00093-0350-01	100	20	2,000
1/22/2018	BUPREN/NALOX 8/2MG SL TABLETS	00228-3155-73	30	72	2,160
1/22/2018	BUTAL/APAP/CAF/COD 50/325/40/30MG CAP	00591-3220-01	100	1	100
1/22/2018	BUTAL/ASA/CAF/COD 50/325/40/30MG CAP	00591-3546-01	100	7	700
1/22/2018	CARISOPRODOL 350MG TABLETS	00591-5513-05	500	12	6,000
1/22/2018	CHLORDIAZEPOXIDE HCL CAPSULES 10MG	00555-0033-02	100	9	900
1/22/2018	CLONAZEPAM 2MG TABLETS	00228-3005-11	100	24	2,400
1/22/2018	CLONAZEPAM TABLETS 1MG	00093-0833-01	100	48	4,800
1/22/2018	CLONAZEPAM TABLETS 1MG	00093-0833-05	500	48	24,000
1/22/2018	CLONAZEPAM TABLETS 2MG	00093-0834-01	100	48	4,800
1/22/2018	GABAPENTIN 100MG CAPSULES	45963-0555-50	500	12	6,000




Pharmaceuticals

Date (cont.)	Product	NDC	Size	Quantity	Total Dosage Units
1/22/2018	LORAZEPAM 0.5MG TABLETS	00591-0240-10	1000	6	6,000
1/22/2018	LORAZEPAM 0.5MG TABLETS	00591-0240-05	500	12	6,000
1/22/2018	LORAZEPAM 1MG TABLETS	00591-0241-01	100	12	1,200
1/22/2018	LORAZEPAM 1MG TABLETS	00591-0241-10	1000	6	6,000
1/22/2018	TEMAZEPAM 15MG CAPSULES	00228-2076-10	100	48	4,800
1/22/2018	ZALEPLON CAPSULES 10MG	00093-5269-01	100	12	1,200
1/22/2018	ZOLPIDEM TARTRATE TABLETS 10MG	00093-0074-01	100	60	6,000

Additionally, pursuant to our investigation, we have suspended all sales of controlled substances to this registrant, pending any further investigation, if it shall become warranted. If you have any questions or concerns, or need any further information, feel free to contact me. My office number is 215.293.6378.

Sincerely,




August 22, 2017

Drug Enforcement Administration Attn: Donetta Spears Diversion Program Manager William J. Green Federal Building 600 Arch Street, Room 10224 Philadelphia, PA 19106

Red	action-O	ther To	eva	Pro	oduct	
Date	Product	NDC	Size	Quantity	Total Dosage Units	1
	Redact	tion-Other Teva Prod	uct			

If you have any questions or concerns, or need any further information, feel free to contact me. My office number is 215.293.6378.

Sincerely,



June 8, 2017

Drug Enforcement Administration Attn: Donetta Spears Diversion Program Manager William J. Green Federal Building 600 Arch Street, Room 10224 Philadelphia, PA 19106

Re: Suspicious Order Report

Dear Ms. Spears,


In accordance with 21C.F.R. § 1301.74(b), I am submitting this report of controlled substance orders we have deemed to be suspicious. The orders were placed by the following registrant:

EMED Medical Company 11551 Adie Rd Maryland Heights, MO 63043-6304 RE0357271

Date	Product	NDC	Size	Quantity	Total Dosage Units
4/28/2017	CARISOPRODOL 350MG TAB 500	00591-5513-05	500	48	24,000

Additionally, pursuant to our investigation, we have suspended all sales of controlled substances to this registrant, pending any further investigation, if it shall become warranted. If you have any questions or concerns, or need any further information, feel free to contact me. My office number is 215.293.6378.

Sincerely,



April 19, 2017

Drug Enforcement Administration Attn: Donetta Spears Diversion Program Manager William J. Green Federal Building 600 Arch Street, Room 10224 Philadelphia, PA 19106

Re: Suspicious Order Report

Dear Ms. Spears,


In accordance with 21C.F.R. § 1301.74(b), I am submitting this report of controlled substance orders we have deemed to be suspicious. The orders were placed by the following registrant:

EMED Medical Company 11551 Adie Rd Maryland Heights, MO 63043-6304 RE0357271

Date	Product	NDC	Size	Quantity	Total Dosage Units
4/11/2017	HYDROCODONE/APAP 10/325MG TAB 500	00591-2612-05	500	270	135,000
4/14/2017	HYDROCODONE/APAP 10/325MG TAB 500	00591-2612-05	500	270	135,000

Additionally, pursuant to our investigation, we have suspended all sales of controlled substances to this registrant, pending any further investigation, if it shall become warranted. If you have any questions or concerns, or need any further information, feel free to contact me. My office number is 215.293.6378.

Sincerely,



April 19, 2017

Drug Enforcement Administration Attn: Donetta Spears Diversion Program Manager William J. Green Federal Building 600 Arch Street, Room 10224 Philadelphia, PA 19106

Re: Suspicious Order Report

Dear Ms. Spears,


In accordance with 21C.F.R. § 1301.74(b), I am submitting this report of controlled substance orders we have deemed to be suspicious. The orders were placed by the following registrant:

D-V Medical Supply 2000 W. 135th Street Gardena, CA 90249 RD0233938

Date	Product	NDC	Size	Quantity	Total Dosage Units
4/5/2017	BUPRENORPHINE 8MG SL TABLETS 30	00228-3153-03	30	24	720
4/5/2017	CARISOPRODOL 350MG TABLETS 500	00591-5513-05	500	72	36,000
4/5/2017	CARISOPRODOL 350MG TABLETS 500	00591-5513-05	500	72	36,000

Additionally, pursuant to our investigation, we have suspended all sales of controlled substances to this registrant, pending any further investigation, if it shall become warranted. If you have any questions or concerns, or need any further information, feel free to contact me. My office number is 215.293.6378.

Sincerely,



April 19, 2017

Drug Enforcement Administration Attn: Donetta Spears Diversion Program Manager William J. Green Federal Building 600 Arch Street, Room 10224 Philadelphia, PA 19106

Re: Suspicious Order Report

Dear Ms. Spears,


In accordance with 21C.F.R. § 1301.74(b), I am submitting this report of controlled substance orders we have deemed to be suspicious. The orders were placed by the following registrant:

D-V Medical Supply 2000 W. 135th Street Gardena, CA 90249 RD0233938

Date	Product	NDC	Size	Quantity	Total Dosage Units
4/5/2017	BUPRENORPHINE 8MG SL TABLETS 30	00228-3153-03	30	24	720
4/5/2017	CARISOPRODOL 350MG TABLETS 500	00591-5513-05	500	72	36,000
4/5/2017	CARISOPRODOL 350MG TABLETS 500	00591-5513-05	500	72	36,000

Additionally, pursuant to our investigation, we have suspended all sales of controlled substances to this registrant, pending any further investigation, if it shall become warranted. If you have any questions or concerns, or need any further information, feel free to contact me. My office number is 215.293.6378.

Sincerely,



August 19, 2015

Drug Enforcement Administration Attn: Donetta Spears Diversion Program Manager William J. Green Federal Building 600 Arch Street, Room 10224 Philadelphia, PA 19106

Re: Suspicious Order Report

Dear Ms. Spears,


In accordance with 21C.F.R. § 1301.74(b), I am submitting this report of controlled substance orders we have deemed to be suspicious. The orders were placed by the following registrant:

BLOODWORTH WHOLESALE DRUGS 2128 Yank Lamb Drive Tifton, GA 31794 PB0167127

Date	Product	NDC	Size	Quantity	Total Dosage Units
7/24/2015	ACETAMINOPHEN & CODEINE TB 300/30MG	00093-0150-01	100	50	5,000
6/11/2015	ACETAMINOPHEN & CODEINE TB 300/30MG	00093-0150-10	1000	192	192,000

If you have any questions or concerns, or need any further information, feel free to contact me. My office number is 215.293.6378.

Sincerely,



July 31, 2015

Drug Enforcement Administration Attn: Donetta Spears Diversion Program Manager William J. Green Federal Building 600 Arch Street, Room 10224 Philadelphia, PA 19106

Re: Suspicious Order Report

Dear Ms. Spears,


In accordance with 21C.F.R. § 1301.74(b), I am submitting this report of controlled substance orders we have deemed to be suspicious. The orders were placed by the following registrant:

Osborn Drugs 103 S Main Miami, OK 74354 R00470601

Date	Product	NDC	Size	Quantity	Total Dosage Units
5/4/2015	ACETAMINOPHEN & CODEINE TB 300/60MG 100	00093-0350-01	100	60	6,000
Redaction - Other Teva Product		,		ther Teva Prod	

If you have any questions or concerns, or need any further information, feel free to contact me. My office number is 215.293.6378.

Sincerely,



June 25, 2015

Drug Enforcement Administration Attn: Donetta Spears Diversion Program Manager William J. Green Federal Building 600 Arch Street, Room 10224 Philadelphia, PA 19106

Re: Suspicious Order Report

Dear Ms. Spears,

In accordance with 21C.F.R. § 1301.74(b), I am submitting this report of controlled substance orders we have deemed to be suspicious. The orders were placed by the following registrant:

Richie Pharmacal LLC 119 State Avenue Glasgow, KY 42141 RR0355683

Date	Product	NDC	Size	Quantity	Total Dosage Units
6/23/2015	ESTAZOLAM TABLETS 2 MG	00093-0130-01	100	36	3,600
6/24/2015	BUPRENORPHINE/NALOXONE 2MG/0.5MG	00093-5720-56	30	12	360
6/24/2015	BUPRENORPHINE/NALOXONE 8MG/2MG	00093-5721-56	30	288	8,640

If you have any questions or concerns, or need any further information, feel free to contact me. My office number is 215.293.6378.

Sincerely,

Joseph Tomkiewicz Diversion Operations Manager Teva Pharmaceuticals



March 30, 2018


Drug Enforcement Administration Attn: Luke Braxton Diversion Program Manager William J. Green Federal Building 600 Arch Street, Room 10224 Philadelphia, PA 19106

Re: Suspicious Order Report

Dear Mr. Braxton,


In accordance with 21C.F.R. § 1301.74(b), I am submitting this report of controlled substance orders we have deemed to be suspicious. The orders were placed by the following registrant:

ROCHESTER DRUG CO-OPERATIVE INC NJ 116 LEHIGH DRIVE FAIRFIELD, NJ 07004 RR0480676



We have previously suspended all sales of controlled substances to this registrant. If you have any questions or concerns, or need any further information, feel free to contact me. My office number is 215.293.6378.

Sincerely,



February 21, 2018


Drug Enforcement Administration Attn: Luke Braxton Diversion Program Manager William J. Green Federal Building 600 Arch Street, Room 10224 Philadelphia, PA 19106

Re: Suspicious Order Report

Dear Mr. Braxton,

Redaction - Other Teva Product

Sincerely,



February 15, 2018

Drug Enforcement Administration Attn: Luke Braxton Diversion Program Manager William J. Green Federal Building 600 Arch Street, Room 10224 Philadelphia, PA 19106

Re: Suspicious Order Report

Dear Mr. Braxton,


In accordance with 21C.F.R. § 1301.74(b), I am submitting this report of controlled substance orders we have deemed to be suspicious. The orders were placed by the following registrant:

ROCHESTER DRUG CO-OPERATIVE INC 50 JETVIEW DRIVE ROCHESTER, NY 14624 PR0003032

Date	Product	NDC	Size	Quantity	Total Dosage Units			
	Redaction - Other Teva Product							

Additionally, pursuant to previous investigation, we have suspended all sales of controlled substances to this registrant. If you have any questions or concerns, or need any further information, feel free to contact me. My office number is 215.293.6378.

Sincerely,



February 13, 2018

Drug Enforcement Administration Attn: Luke Braxton Diversion Program Manager William J. Green Federal Building 600 Arch Street, Room 10224 Philadelphia, PA 19106

Re: Suspicious Order Report

Dear Mr. Braxton,


In accordance with 21C.F.R. § 1301.74(b), I am submitting this report of controlled substance orders we have deemed to be suspicious. The orders were placed by the following registrant:

ROCHESTER DRUG CO-OPERATIVE INC 50 JETVIEW DRIVE ROCHESTER, NY 14624 PR0003032

Date	Product	NDC	Size	Quantity	Total Dosage Units
[other Teva Produc	t		

Additionally, pursuant to previous investigation, we have suspended all sales of controlled substances to this registrant. If you have any questions or concerns, or need any further information, feel free to contact me. My office number is 215.293.6378.

Sincerely,



February 7, 2018

Drug Enforcement Administration Attn: Luke Braxton Diversion Program Manager William J. Green Federal Building 600 Arch Street, Room 10224 Philadelphia, PA 19106

Re: Suspicious Order Report

Dear Mr. Braxton,


In accordance with 21C.F.R. § 1301.74(b), I am submitting this report of controlled substance orders we have deemed to be suspicious. The orders were placed by the following registrant:

ROCHESTER DRUG CO-OPERATIVE INC 50 JETVIEW DRIVE ROCHESTER, NY 14624 PR0003032

Date	Product	NDC	Size	Quantity	Total Dosage Units
2/6/2018	CHLORDIAZEPOXIDE HCL CAPSULES 25MG	00555-0159-04	500	6	3,000

Additionally, pursuant to previous investigation, we have suspended all sales of controlled substances to this registrant. If you have any questions or concerns, or need any further information, feel free to contact me. My office number is 215.293.6378.

Sincerely,



February 6, 2018

Drug Enforcement Administration Attn: Luke Braxton Diversion Program Manager William J. Green Federal Building 600 Arch Street, Room 10224 Philadelphia, PA 19106

Re: Suspicious Order Report

Dear Mr. Braxton,

In accordance with 21C.F.R. § 1301.74(b), I am submitting this report of controlled substance orders we have deemed to be suspicious. The orders were placed by the following registrant:

ROCHESTER DRUG CO-OPERATIVE INC 50 JETVIEW DRIVE ROCHESTER, NY 14624 PR0003032

Date	Product	NDC	Size	Quantity	Total Dosage Units
2/5/2018	NUVIGIL TAB 250MG	63459-0225-30	30	12	360

Additionally, pursuant to our investigation, we have suspended all sales of controlled substances to this registrant, pending any further investigation, if it shall become warranted. If you have any questions or concerns, or need any further information, feel free to contact me. My office number is 215.293.6378.

Sincerely,



February 6, 2018

Drug Enforcement Administration Attn: Luke Braxton Diversion Program Manager William J. Green Federal Building 600 Arch Street, Room 10224 Philadelphia, PA 19106

Re: Suspicious Order Report

Dear Mr. Braxton,


In accordance with 21C.F.R. § 1301.74(b), I am submitting this report of controlled substance orders we have deemed to be suspicious. The orders were placed by the following registrant:

ROCHESTER DRUG CO-OPERATIVE INC NJ 116 LEHIGH DRIVE FAIRFIELD, NJ 07004 RR0480676

Date	Product	NDC	Size	Quantity	Total Dosage Units
1/30/2018	GABAPENTIN 400MG CAPSULES	45963-0557-50	500	12	6,000
1/30/2018	GABAPENTIN 300MG CAPSULES	45963-0556-50	500	24	12,000
1/30/2018	GABAPENTIN 100MG CAPSULES	45963-0555-50	500	24	12,000
1/30/2018	GABAPENTIN TABLETS 600MG	00093-4443-05	500	1	500
1/30/2018	GABAPENTIN TABLETS 600MG	00093-4443-10	1000	6	6,000
2/5/2018	ADIPEX-P TABLETS	57844-0009-01	100	12	1,200

Additionally, pursuant to our investigation, we have suspended all sales of controlled substances to this registrant, pending any further investigation, if it shall become warranted. If you have any questions or concerns, or need any further information, feel free to contact me. My office number is 215.293.6378.

Sincerely,



January 18, 2018

Drug Enforcement Administration Attn: Luke Braxton Diversion Program Manager William J. Green Federal Building 600 Arch Street, Room 10224 Philadelphia, PA 19106

Re: Suspicious Order Report

Dear Mr. Braxton,

In accordance with 21C.F.R. § 1301.74(b), I am submitting this report of controlled substance orders we have deemed to be suspicious. The orders were placed by the following registrant:

ROCHESTER DRUG CO-OPERATIVE INC 50 JETVIEW DRIVE ROCHESTER, NY 14624 PR0003032


Date	Product	NDC	Size	Quantity	Total Dosage Units
1/18/2018	LORAZEPAM 1MG TABLETS	00591-0241-01	100	48	4,800
1/18/2018	BUPREN/NALOX 2/0.5MG TABLETS 30 BL	00228-3154-73	30	24	720
1/18/2018	LORAZEPAM 2MG TABLETS 100	00591-0242-01	100	12	1,200
1/18/2018	MODAFINIL 100MG TABLETS 30	00591-3499-30	30	18	540
1/18/2018	OXAZEPAM 15MG CAPSULES 100	00228-2069-10	100	36	3,600
1/18/2018	TEMAZEPAM 15MG CAPSULES 100	00228-2076-10	100	24	2,400
1/18/2018	BUTAL/APAP/CAF/COD 50/325/40/30MG CAP100	00591-3220-01	100	1	100
1/18/2018	CARISOPRODOL 350MG TABLETS 100	00591-5513-01	100	11	1,100
1/18/2018	ESTAZOLAM 2MG TABLETS 100	00591-0745-01	100	1	100
1/18/2018	LORAZEPAM 0.5MG TABLETS 500	00591-0240-05	500	36	18,000
1/18/2018	LORAZEPAM 0.5MG TABLETS 1000	00591-0240-10	1000	54	54,000
1/18/2018	LORAZEPAM 1MG TABLETS 1000	00591-0241-10	1000	18	18,000
1/18/2018	LORAZEPAM 1MG TABLETS 500	00591-0241-05	500	12	6,000

Additionally, pursuant to our investigation, we have suspended all sales of controlled substances to this registrant, pending any further investigation, if it shall become warranted. If you have any questions or concerns, or need any further information, feel free to contact me. My office number is 215.293.6378.



Pharmaceuticals

Sincerely,



January 17, 2018

Drug Enforcement Administration Attn: Luke Braxton Diversion Program Manager William J. Green Federal Building 600 Arch Street, Room 10224 Philadelphia, PA 19106

Re: Suspicious Order Report

Dear Mr. Braxton,


In accordance with 21C.F.R. § 1301.74(b), I am submitting this report of controlled substance orders we have deemed to be suspicious. The orders were placed by the following registrant:

ROCHESTER DRUG CO-OPERATIVE INC 50 JETVIEW DRIVE ROCHESTER, NY 14624 PR0003032

Date	Product	NDC	Size	Quantity	Total Dosage Units
1/17/2018	GABAPENTIN 300MG CAPSULES	45963-0556-11	100	75	7,200
1/17/2018	GABAPENTIN 100MG CAPSULES	45963-0555-50	500	48	24,000

Additionally, pursuant to our investigation, we have suspended all sales of controlled substances to this registrant, pending any further investigation, if it shall become warranted. If you have any questions or concerns, or need any further information, feel free to contact me. My office number is 215.293.6378.

Sincerely,



January 17, 2018

Drug Enforcement Administration Attn: Luke Braxton Diversion Program Manager William J. Green Federal Building 600 Arch Street, Room 10224 Philadelphia, PA 19106

Re: Suspicious Order Report

Dear Mr. Braxton,

In accordance with 21C.F.R. § 1301.74(b), I am submitting this report of controlled substance orders we have deemed to be suspicious. The orders were placed by the following registrant:


ROCHESTER DRUG CO-OPERATIVE INC NJ 116 LEHIGH DRIVE FAIRFIELD, NJ 07004 RR0480676

	Product	NDC	Size	Quantity	Total Dosage Units
1/16/2018	ACETAMINOPHEN & CODEINE TB 300/15MG	00093-0050-01	100	20	2,000
1/16/2018	ACETAMINOPHEN & CODEINE TB 300/30MG	00093-0150-01	100	10	1,000
1/16/2018	ACETAMINOPHEN & CODEINE TB 300/60MG	00093-0350-01	100	70	7,000
	Redaction -	Other Teva Product		•	
1/16/2018	BUTAL/ASA/CAF/COD 50/325/40/30MG CAP	00591-3546-01	100	11	1,100



Additionally, pursuant to our investigation, we have suspended all sales of controlled substances to this registrant, pending any further investigation, if it shall become warranted. If you have any questions or concerns, or need any further information, feel free to contact me. My office number is 215.293.6378.

Sincerely,



January 16, 2018

Drug Enforcement Administration Attn: Luke Braxton Diversion Program Manager William J. Green Federal Building 600 Arch Street, Room 10224 Philadelphia, PA 19106


Re: Suspicious Order Report

Dear Mr. Braxton,

In accordance with 21C.F.R. § 1301.74(b), I am submitting this report of controlled substance orders we have deemed to be suspicious. The orders were placed by the following registrant:

ROCHESTER DRUG CO-OPERATIVE INC NJ 116 LEHIGH DRIVE FAIRFIELD, NJ 07004 RR0480676

Date	Product	NDC	Size	Quantity	Total Dosage Units
12/28/2017	OXYCODONE HCL 15MG TABLETS	00228-2878-11	100	48	4,800
12/28/2017	OXYCODONE HCL 30MG TABLETS	00228-2879-11	100	360	36,000
1/9/2018	OXYCODONE HCL 15MG TABLETS	00228-2878-11	100	96	9,600
1/9/2018	OXYCODONE HCL 30MG TABLETS	00228-2879-11	100	408	40,800
1/9/2018	OXYCODONE/ASA 4.8355/325MG TAB	00591-3551-01	100	3	300
1/11/2018	ACETAMINOPHEN & CODEINE TB 300/30MG	00093-0150-01	100	20	2,000
1/11/2018	ACETAMINOPHEN & CODEINE TB 300/30MG	00093-0150-10	1000	6	6,000
1/11/2018	ACETAMINOPHEN & CODEINE TB 300/60MG	00093-0350-01	100	50	5,000
1/11/2018	ACTIQ BKU 200MCG 1CTNX30 US	63459-0502-30	30	2	60
1/11/2018	ACTIQ BKU 600MCG 1CTNX30 US	63459-0506-30	30	1	30
1/11/2018	CLONAZEPAM TABLETS 1MG	00093-0833-01	100	24	2,400
1/11/2018	CLONAZEPAM TABLETS 1MG	00093-0833-10	1000	66	66,000
1/11/2018	CLONAZEPAM TABLETS 1MG	00093-0833-05	500	120	60,000
1/11/2018	CLONAZEPAM TABLETS 2MG	00093-0834-01	100	24	2,400
1/11/2018	GABAPENTIN 100MG CAPSULES	45963-0555-50	500	12	6,000
1/11/2018	GABAPENTIN TABLETS 600MG	00093-4443-05	500	7	3,500
1/11/2018	ZALEPLON CAPSULES 10MG	00093-5269-01	100	12	1,200
1/11/2018	ZALEPLON CAPSULES 5MG	00093-5268-01	100	12	1,200
1/11/2018	ZOLPIDEM TARTRATE TABLETS 10MG	00093-0074-01	100	24	2,400
1/12/2018	HYDROCODONE/IBUPROFEN 7.5/200MG TAB	62037-0524-01	100	7	700
1/12/2018	METHYLPHENIDATE HCL 36 MG ER TABLETS	00591-2717-30	30	24	720
1/12/2018	METHYLPHENIDATE HCL 54 MG ER TABLETS	00591-2718-01	100	12	1,200
1/12/2018	OXYCODONE HCL 15MG TABLETS	00228-2878-11	100	48	4,800



Additionally, pursuant to our investigation, we have suspended all sales of controlled substances to this registrant, pending any further investigation, if it shall become warranted. If you have any questions or concerns, or need any further information, feel free to contact me. My office number is 215.293.6378.

Sincerely,



December 1, 2014

Drug Enforcement Administration Attn: Donetta Spears Diversion Program Manager William J. Green Federal Building 600 Arch Street, Room 10224 Philadelphia, PA 19106

Re: Suspicious Order Report

Dear Ms. Spears,

In accordance with 21C.F.R. § 1301.74(b), I am submitting this report of controlled substance orders we have deemed to be suspicious. All orders were placed by the following registrant:

Richie Pharmacal LLC 119 State Avenue Glasgow, KY 42141 RR0355683

Date	Product	NDC	Size	Quantity	Total Dosage Units
10/23/2014	ACETAMINOPHEN & CODEINE TB 300/30MG	00093-0150-01	100	40	4,000
10/23/2014	ACETAMINOPHEN & CODEINE TB 300/60MG	00093-0350-01	100	90	9,000
10/23/2014	ACETAMINOPHEN & CODEINE TB 300/60MG	00093-0350-05	500	48	24,000
10/24/2014	ACETAMINOPHEN & CODEINE TB 300/60MG	00093-0350-01	100	50	5,000
10/24/2014	ACETAMINOPHEN & CODEINE TB 300/60MG	00093-0350-05	500	48	24,000

Additionally, pursuant to our investigation, we have suspended all sales of controlled substances to this registrant, pending any further investigation, if it shall become warranted. If you have any questions or concerns, or need any further information, feel free to contact me. My office number is 215.293.6378.

Sincerely,

Joseph Tomkiewicz Diversion Operations Manager Teva Pharmaceuticals



TEVA_MDL_A_02342525